Results 21 to 30 of about 2,436,024 (405)

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Annals of Oncology, 2018
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can result in impressive ...
T. Chan, M. Yarchoan, E. Jaffee, C. Swanton, S. Quezada, A. Stenzinger, Solange Peters   +6 more
semanticscholar   +1 more source

Magnons in Ferromagnetic Metallic Manganites [PDF]

, 2007
Ferromagnetic (FM) manganites, a group of likely half-metallic oxides, are of special interest not only because they are a testing ground of the classical doubleexchange interaction mechanism for the colossal magnetoresistance, but also because they ...
Dai, Pengcheng, Fernandez-Baca, J. A., Plummer, E. W., Sha, Hao, Ye, F., Zhang, Jiandi   +5 more
core   +1 more source

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2022
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel
John A Thompson, B. Schneider, J. Brahmer, Amaka Achufusi, Philippe Armand, Meghan K Berkenstock, S. Bhatia, L. Budde, S. Chokshi, M. Davies, Amro Elshoury, Yaron Gesthalter, A. Hegde, M. Jain, Benjamin H Kaffenberger, M. Lechner, Tianhong Li, A. Marr, S. McGettigan, J. McPherson, T. Medina, N. Mohindra, A. Olszanski, O. Oluwole, S. Patel, P. Patil, S. Reddy, Mabel Ryder, B. Santomasso, S. Shofer, J. Sosman, Yinghong Wang, V. G. Zaha, M. Lyons, M. Dwyer, Lisa E Hang   +35 more
semanticscholar   +1 more source

Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications [PDF]

, 2019
© 2019 Salek, Lussier Hoskyn, Johns, Allen and Sehgal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).This analysis follows our recent study showing that Canadian public reimbursement delays
Adcock, Balasubramanian, Bertozzi, Bruce, Cave, Curtis, Hazell, Jeffcott, Milliken, Millson, Navarria, O’Connor, Pessina, Russo, Salek, von Elm   +15 more
core   +3 more sources

Precision oncology: the intention-to-treat analysis fallacy. [PDF]

, 2020
It has recently been suggested that precision oncology studies should be reanalysed using the intention-to-treat (ITT) methodology developed for randomized controlled clinical trials.
Kato, Shumei, Kurzrock, Razelle, Okamura, Ryosuke, Sicklick, Jason K   +3 more
core   +1 more source

Polypharmacy and potentially inappropriate medication use in geriatric oncology. [PDF]

, 2016
Polypharmacy is a highly prevalent problem in older persons, and is challenging to assess and improve due to variations in definitions of the problem and the heterogeneous methods of medication review and reduction.
Aparicio, Appleton, Badgwell, Balducci, Budnitz, Bushardt, Caillet, Currow, de Glas, Dimitrow, Elliot, Fede, Freyer, Fried, Gajra, Gillette, Gnjidic, Gu, Guaraldo, Guthrie, Gómez, Hajjar, Hamaker, Hanigan, Hanlon, Hilmer, Horgan, Hovstadius, Huiart, Hurria, Institute of Medicine (U.S.). Committee on Identifying Priority Areas for Quality Improvement, Iyer, Jolly, Kalsi, Kanesvaran, Kantor, Kierner, Kim, Klepin, Kohn, Kohn, Korc-Grodzicki, Kouladjian, Lees, Maggiore, Maggiore, Nightingale, O'Mahony, Palumbo, Panel, Parks, Patterson, Payne, Prithviraj, Riechelmann, Saarelainen, Samsa, Scott, Sehgal, Shah, Todd, Todd, Turner, Turner, Woopen, Şenel   +65 more
core   +2 more sources

End-stage head and neck cancer: coping mechanism [PDF]

, 2017
Coping mechanisms are patients’ means of adapting to stressful situations and involve psychological and physical changes in behavior. Patients adapt to head and neck cancer in a variety of ways.
Berteşteanu, Serban V.G., Paun, Oana, Popescu, Bogdan, Scăunaşu, Razvan V.   +3 more
core   +3 more sources

Orofacial pain in oncology: use of a new analgesic peptide tafalgin

Опухоли головы и шеи, 2023
In patients with head and neck tumors severe pain is more common than in patients with malignant neoplasms of other locations. At a third of patients, pain is the first characteristic of the disease, and after diagnosis, one half of the patients are ...
G. R. Abuzarova, R. R. Sarmanaeva, G. S. Alekseeva, S. V. Kuznetsov, A. R. Gevorkov, N. A. Fedorenko, D. A. Zaretskaya   +6 more
doaj   +1 more source

Adjuvant therapy for early uterine high-grade leiomyosarcoma [PDF]

, 2019
TO THE EDITOR: The article by Hensley et al1 recently published in Journal of Clinical Oncology was interesting, even if apparently negative (Gynecology Oncology Group [GOG]-0277 randomized phase III trial). The study investigated the activity and safety
Panici, P. B., Tomao, F., Tomao, S.
core   +1 more source

IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures

bioRxiv, 2020
Motivation Recent advance in next generation sequencing has triggered the rapid accumulation of publicly available multi-omics datasets. The application of integrated omics to exploring robust signatures for clinical translation is increasingly ...
D. Zeng, Zilan Ye, Guangchuang Yu, Jiani Wu, Yi Xiong, R. Zhou, Wenjun Qiu, N. Huang, Li Sun, J. Bin, Y. Liao, Min Shi, W. Liao   +12 more
semanticscholar   +1 more source